Tag Archives: Leah R. Cann

Mirati Therapeutics (MRTX) Gets a Buy Rating from Oppenheimer

In a report released yesterday, Leah R. Cann from Oppenheimer maintained a Buy rating on Mirati Therapeutics (NASDAQ: MRTX), with a price target of $62. The company’s shares closed on Friday at $40.01. Cann noted: “The data presented at ESMO

Tesaro (TSRO) Received its Third Buy in a Row

After Leerink Partners and Cantor Fitzgerald gave Tesaro (NASDAQ: TSRO) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Leah R. Cann maintained a Buy rating on Tesaro today and set a price target

Clovis Oncology (CLVS) Gets a Hold Rating from Oppenheimer

In a report released today, Leah R. Cann from Oppenheimer maintained a Hold rating on Clovis Oncology (NASDAQ: CLVS). The company’s shares opened today at $30.90, close to its 52-week low of $26.21. Cann said: “The initial data for the

Intellia Therapeutics (NTLA) Gets a Hold Rating from Oppenheimer

In a report released today, Leah R. Cann from Oppenheimer maintained a Hold rating on Intellia Therapeutics (NASDAQ: NTLA). The company’s shares opened today at $24.35. Cann observed: “We believe ex-vivo therapies are a lower risk approach for use of

Analysts Are Bullish on These Healthcare Stocks: MEI Pharma (MEIP), uniQure NV (QURE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MEI Pharma (NASDAQ:MEIP) and uniQure NV (NASDAQ:QURE) with bullish sentiments. MEI Pharma (MEIP) Oppenheimer analyst Leah R. Cann maintained a Buy rating

Crispr Therapeutics AG (CRSP) Gets a Hold Rating from Oppenheimer

Oppenheimer analyst Leah R. Cann maintained a Hold rating on Crispr Therapeutics AG (NASDAQ: CRSP) today. The company’s shares opened today at $36.64. Cann said: “CTX001 has previously shown impressive data in both beta thalassemia and sickle cell anemia, as